Fondaparinux versus enoxaprin in the management of acute coronary syndromes in Switzerland: A cost comparison analysis | Zendy

Michel P. Kossovsky | Zendy; PF Keller | Zendy; F Mach | Zendy; JM Gaspoz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fondaparinux versus enoxaprin in the management of acute coronary syndromes in Switzerland: A cost comparison analysis

Author(s) -

Michel P. Kossovsky,

PF Keller,

F Mach,

JM Gaspoz

Publication year - 2012

Publication title -

schweizerische medizinische wochenschrift

Language(s) - English

Resource type - Journals

ISSN - 0036-7672

DOI - 10.4414/smw.2012.13536

Subject(s) - medicine , fondaparinux , emergency medicine , cardiology , intensive care medicine , venous thromboembolism , thrombosis

Anticoagulation therapy is routinely used in cases of non ST-segment elevation acute coronary syndromes (NSTE-ACS). The most commonly used drug in such events is enoxaparin, a low molecular weight heparin. Fondaparinux, a synthetic pentasaccharide, is as effective as enoxaparin in terms of survival or residual angina pectoris and significantly reduces bleeding complications. The purpose of this study was to assess the magnitude of cost reductions if enoxaparin were replaced by fondaparinux in Switzerland

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research